Association of C-reactive Protein-albumin-lymphocyte Index (CALLY) With All-cause Mortality in Diabetic Patients
Sponsored by Kunming Children's Hospital
About this trial
Last updated a year ago
Study ID
20250508CALLY
Status
Completed
Type
Observational
Placebo
No
Accepting
40+ Years
All Sexes
Trial Timing
Ended a year ago
What is this trial about?
Based on retrospective cohort data from 3,988 diabetic patients in the NHANES database, this study is the first to show a significant negative correlation between the CALLY index and all-cause mortality in diabetic patients, with good predictive ability for their survival risk. Our findings can help clinicians better assess disease progression in diabetic patients and provide a reference for personalized, precision medicine.
What are the participation requirements?
Inclusion Criteria
(1) self-reported doctor-diagnosed diabetes; (2) fasting blood glucose ≥ 7.0 mmol/L; (3) two-hour oral glucose tolerance test blood glucose ≥ 11.1 mmol/L; (4) glycated hemoglobin A1c (HbA1c) ≥ 6.5%; or (5) use of hypoglycemic medication.
Exclusion Criteria